Introduction: Retention of I-131 in the body of patients with differentiated thyroid carcinoma (DTC) has a direct effect on therapeutic outcome of radioiodine therapy. There are several factors that may influence retention time of radioiodine in the body of these patients. In this study we are going to assess effects of administered radioiodine activity, serum thyroid stimulating hormone (TSH) level and also admission/administration number on the retention of I-131 in the body of DTC patients. Methods: Number of 92 DTC patients, with different TSH levels ranged from 32 mIU/ml to 250 mIU/ml, was treated with different I-131 activities ranged from 1850 MBq to 7400MBq. They received one, two or three sessions of radioiodine therapy based on se...
Background: Radioactive 131I (RAI) therapy is used in patients with differentiated thyroid cancer (D...
BACKGROUND Although radioiodine therapy in differentiated thyroid carcinoma without radioiodine accu...
Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to s...
Radioiodine (131I iodide) has long been a safe, effective and widely used treatment in the managemen...
131I treatment in thyroid cancer patients may induce side effects, including extrathyroidal cancer a...
Radioactive iodine is commonly administered following thyroidectomy for differentiated thyroid carci...
Background: Radioactive 131I (RAI) therapy is used in patients with differentiated thyroid cancer (D...
Purpose: To analyse the activity uptakes, effective half-lives and time-integrated activities, of re...
The aim of this study was to measure the radiation exposure rate from differentiated thyroid carcino...
Despite the wide use of radioiodine treatment for hyperthyroidism, the best approach to radioiodine ...
The amount of 131I necessary for successful ablation in patients with differentiated thyroid cancer ...
Purpose: Effective half life of I-131 (Teff) in patients with differentiated thyroid cancer treated ...
Publications investigating the effect of radioactive iodine (131I) therapy on the circulating periph...
BACKGROUND: The aim of this paper was to compare the results of postoperative I-131 remnant ablation...
Differentiated thyroid cancer (DTC) is the most common endocrine malignancy with the highest mortali...
Background: Radioactive 131I (RAI) therapy is used in patients with differentiated thyroid cancer (D...
BACKGROUND Although radioiodine therapy in differentiated thyroid carcinoma without radioiodine accu...
Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to s...
Radioiodine (131I iodide) has long been a safe, effective and widely used treatment in the managemen...
131I treatment in thyroid cancer patients may induce side effects, including extrathyroidal cancer a...
Radioactive iodine is commonly administered following thyroidectomy for differentiated thyroid carci...
Background: Radioactive 131I (RAI) therapy is used in patients with differentiated thyroid cancer (D...
Purpose: To analyse the activity uptakes, effective half-lives and time-integrated activities, of re...
The aim of this study was to measure the radiation exposure rate from differentiated thyroid carcino...
Despite the wide use of radioiodine treatment for hyperthyroidism, the best approach to radioiodine ...
The amount of 131I necessary for successful ablation in patients with differentiated thyroid cancer ...
Purpose: Effective half life of I-131 (Teff) in patients with differentiated thyroid cancer treated ...
Publications investigating the effect of radioactive iodine (131I) therapy on the circulating periph...
BACKGROUND: The aim of this paper was to compare the results of postoperative I-131 remnant ablation...
Differentiated thyroid cancer (DTC) is the most common endocrine malignancy with the highest mortali...
Background: Radioactive 131I (RAI) therapy is used in patients with differentiated thyroid cancer (D...
BACKGROUND Although radioiodine therapy in differentiated thyroid carcinoma without radioiodine accu...
Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to s...